These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8865525

  • 1. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
    Bröijersén A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P.
    Thromb Haemost; 1996 Aug; 76(2):171-6. PubMed ID: 8865525
    [Abstract] [Full Text] [Related]

  • 2. Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
    Musiał J, Pajak A, Undas A, Kawalec E, Topór-Madry R, Pazucha T, Grzywacz M, Szczeklik A.
    Thromb Haemost; 1997 Apr; 77(4):697-700. PubMed ID: 9134645
    [Abstract] [Full Text] [Related]

  • 3. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 4. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 5. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
    Vessby B, Lithell H, Boberg J, Hellsing K, Werner I.
    Proc R Soc Med; 1976 Oct; 69 Suppl 2(Suppl 2):32-7. PubMed ID: 798194
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR.
    Drugs Exp Clin Res; 1994 Oct; 20(3):109-13. PubMed ID: 7956717
    [Abstract] [Full Text] [Related]

  • 7. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD.
    Am J Cardiol; 2005 Nov 01; 96(9):1266-72. PubMed ID: 16253595
    [Abstract] [Full Text] [Related]

  • 8. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan 01; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 9. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease.
    Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ.
    Thromb Haemost; 1992 May 04; 67(5):503-6. PubMed ID: 1519208
    [Abstract] [Full Text] [Related]

  • 10. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
    Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, McGrath BP.
    Clin Sci (Lond); 2001 Jul 04; 101(1):93-9. PubMed ID: 11410120
    [Abstract] [Full Text] [Related]

  • 11. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
    Nevard CH, Jurd KM, Lane DA, Philippou H, Haycock GB, Hunt BJ.
    Thromb Haemost; 1997 Dec 04; 78(6):1450-5. PubMed ID: 9423793
    [Abstract] [Full Text] [Related]

  • 12. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct 04; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 13. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F, Ok E, Duman S, Kürsad S, Unsal A, Alev M, Atabay G, Basçi A.
    Adv Perit Dial; 1996 Oct 04; 12():261-5. PubMed ID: 8865916
    [Abstract] [Full Text] [Related]

  • 14. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 04; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
    Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HE, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Am Heart J; 2009 May 04; 157(5):913-8. PubMed ID: 19376321
    [Abstract] [Full Text] [Related]

  • 16. Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects.
    Sutken E, Inal M, Ozdemir F.
    Saudi Med J; 2006 Apr 04; 27(4):453-9. PubMed ID: 16598319
    [Abstract] [Full Text] [Related]

  • 17. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.
    Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A.
    Arterioscler Thromb Vasc Biol; 1996 Nov 04; 16(11):1333-9. PubMed ID: 8911271
    [Abstract] [Full Text] [Related]

  • 18. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC.
    Am J Kidney Dis; 2004 Nov 04; 44(5):832-9. PubMed ID: 15492949
    [Abstract] [Full Text] [Related]

  • 19. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro.
    Torbet J.
    Thromb Haemost; 1995 May 04; 73(5):785-92. PubMed ID: 7482404
    [Abstract] [Full Text] [Related]

  • 20. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds.
    Hattori T, Khan MM, Colman RW, Edmunds LH.
    J Am Coll Cardiol; 2005 Aug 16; 46(4):707-13. PubMed ID: 16098440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.